Biogen Completes $1.75 Billion Notes Issuance

Biogen ( (BIIB) ) has shared an announcement.

On May 12, 2025, Biogen Inc. completed the issuance and sale of $1.75 billion in senior unsecured notes, with varying maturities and interest rates, to retire its outstanding 4.050% Senior Notes due 2025. The company plans to use the proceeds, along with cash on hand, to manage its debt obligations and for general corporate purposes, potentially impacting its financial flexibility and market positioning.

The most recent analyst rating on (BIIB) stock is a Buy with a $316.00 price target. To see the full list of analyst forecasts on Biogen stock, see the BIIB Stock Forecast page.

Spark’s Take on BIIB Stock

According to Spark, TipRanks’ AI Analyst, BIIB is a Neutral.

Biogen’s overall stock score reflects its solid financial stability and attractive valuation, despite revenue decline risks. The technical analysis suggests mixed momentum, while the earnings call highlights strong growth in new products but ongoing challenges in core segments.

To see Spark’s full report on BIIB stock, click here.

More about Biogen

Biogen Inc. operates in the biotechnology industry, focusing on discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases.

Average Trading Volume: 1,750,600

Technical Sentiment Signal: Sell

Current Market Cap: $17.32B

For detailed information about BIIB stock, go to TipRanks’ Stock Analysis page.